FDA Approved: SANDOSTATIN — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

The FDA approved a supplemental application for Sandostatin (octreotide acetate) from Novartis Pharmaceuticals Corporation under NDA 019667.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acromegaly
• Carcinoid Syndrome
• Neuroendocrine Tumor
• Pancreatic Neuroendocrine Tumor
• Vipoma

Drugs mentioned

• Sandostatin (Octreotide acetate)

Snippet

SUPPL AP for SANDOSTATIN (OCTREOTIDE ACETATE)